Mechanism and inhibition of SARS-CoV-2 PLpro
Theresa Klemm(The University of Melbourne), David Komander(Walter and Eliza Hall Institute of Medical Research), Zhong Yan Gan(The University of Melbourne), Alan Riboldi‐Tunnicliffe(Australian Nuclear Science and Technology Organisation), Nathan W. Kuchel(The University of Melbourne), Dale J. Calleja(The University of Melbourne), Jonathan P. Bernardini(University of British Columbia), Marcel Doerflinger(The University of Melbourne), Cody C. Allison(The University of Melbourne), Bernadine G.C. Lu(The University of Melbourne), Jeffrey P. Mitchell(University of California, Davis), Paul P. Geurink(Leiden University), Janet Newman(Freedom to Live), Lachlan W. Richardson(The University of Melbourne), Marc Pellegrini(The University of Melbourne), Christoph Grohmann(The University of Melbourne), Peter E. Czabotar(The University of Melbourne), Gregor Ebert(Helmholtz Zentrum München), Bernhard C. Lechtenberg(Walter and Eliza Hall Institute of Medical Research), Grant Dewson(The University of Melbourne), Kym N. Lowes(The University of Melbourne), James P. Cooney(The University of Melbourne), Guillaume Lessène(The University of Melbourne), Rebecca Feltham(Walter and Eliza Hall Institute of Medical Research), Y. Shibata(The University of Melbourne), Amanda E. Au(The University of Melbourne), Huib Ovaa(Leiden University Medical Center), T. Blackmore(The University of Melbourne)
Cited by 15
Related Papers
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
|Cell Death and Differentiation|2018|6.6k
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
|Science Translational Medicine|2015|541
Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2
|The EMBO Journal|2020|499
Structural insights into the catalytic mechanism of a family 18 exo-chitinase
|Proceedings of the National Academy of Sciences|2001|462
Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin
|Nature Communications|2013|435